TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Citius Pharmaceuticals ( (CTXR) ) just unveiled an update.
On June 9, 2025, Citius Pharmaceuticals filed a Certificate of Amendment to increase its authorized shares significantly, with the approval of stockholders at a special meeting. This amendment, which became effective upon filing with the State of Nevada, raises the authorized capital stock from 26,000,000 to 260,000,000 and common shares from 16,000,000 to 250,000,000. The approval of this amendment reflects a strategic move to expand the company’s capital structure, potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (CTXR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.
Spark’s Take on CTXR Stock
According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.
Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.
To see Spark’s full report on CTXR stock, click here.
More about Citius Pharmaceuticals
Average Trading Volume: 303,346
Technical Sentiment Signal: Sell
Current Market Cap: $8.76M
Find detailed analytics on CTXR stock on TipRanks’ Stock Analysis page.